FDA Making COVID Vax Decision Based on a Study of 10
May 23, 2022, Pfizer-BioNTech1 announced preliminary results from their Phase 2/3 trial evaluating a three-dose vaccine schedule for children 6 months to under 5 years of age would be submitted to the FDA for emergency use authorization (EUA). Many in mainstream media are hailing this development as important to children’s health, writing, “many parents of… Read More »